Start with a free account for 12 free CME credits. Already a subscriber? Sign in.
Chapter 12

Paper Chase #4 | Risks/benefits of Direct Oral Anticoagulants versus Warfarin

Matthew DeLaney, MD, FACEP, FAAEM and Matthieu DeClerk, MD
00:00
03:24
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

BOTTOM LINE: Overall, apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were associated with increased risks of all cause mortality compared with warfarin

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

3.5 AAPA Category 1 Credits certified by Hippo (2018-2019)